Tele: 561.316.3330
Breaking Medical Device News

Saturday, October 16, 2021
HomeDISINFECTION TECHNOLOGY PRODUCTSGermFlare Announces Its Professional Handheld UVC Light Kills 99.99% of MRSA and...

GermFlare Announces Its Professional Handheld UVC Light Kills 99.99% of MRSA and P. Aeruginosa in Laboratory Testing

March 2, 2021

GermFlare, based in Denmark, today proudly reported its handheld UVC light called “GermFlare” to achieve greater than 99.99%, or 4log, inactivation of both Methicillin-Resistant Staphylococcus Aureus (MRSA) and Pseudomonas Aeruginosa (PA) in less than 5 seconds at a distance of 3.9 inches (10 cm).

Testing on the two bacteria strains was conducted by ALS Denmark A/S (part of ALS Laboratories), an accredited global certified laboratory.

GermFlare, UVC

The testing parameters were carefully selected to simulated how the effect of the GermFlare would be in the hands of its core user, the healthcare personnel at hospitals. GermFlare has previously been proven to inactivate SARS-CoV-2 at the Department of Immunology and Microbiology and Department of Infectious Diseases, Hvidovre Hospital, Denmark.

“Our focus is to provide a solution to the global Hospital Acquired Infection (HAI) problem and as MRSA is one of those bacteria our core users fight against every day, we are very pleased with the results.”

“We hope this test and the results can provide some comfort and confidence to the Healthcare personnel working in areas where there is an increased risk of contracting HAIs.”

“When the user starts to incorporate the use of GermFlare more in their daily routines the risk of being infected by any harmful pathogen decreases noticeable, and it could just be a quick 5-second treatment of any hotspots they touch. Even if the nurse forgets to use rubbing alcohol after they touched a door handle, they do not need to worry because if they used the GermFlare it would have killed the harmful pathogens and broken the chain of infection.” – states Flemming Dahlin, Chief Executive Officer, GermFlare.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy